 |
Top 113 medical and healthcare startups in Cambridge
Last updated: April 25, 2024 |
1
Funding: $3B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Funding: $1.5B
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
3
Funding: $1.2B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
4
Funding: $1.1B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
5
Funding: $931.6M
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
6
Funding: $749.5M
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
8
Funding: $603.3M
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
Fulcrum Therapectics to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
9
Funding: $584.2M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
10
Funding: $542.9M
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
11
Funding: $537.8M
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
12
Funding: $536.4M
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.
13
Funding: $520.6M
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
14
Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
15
Funding: $443.6M
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
As a multi-asset, clinical-stage biopharmaceutical company, Spero Therapeutics is focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
16
Funding: $442.5M
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
Akebia Therapeutics develops treatments for ischemia and vascular diseases. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Pursuing a new standard of care for patients with anemia associated with chronic kidney disease (CKD)
17
Funding: $419.3M
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
18
Funding: $407M
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
The mission of CRISPR Therapeutics is to develop transformative gene-based medicines for patients with serious diseases. Our therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR-Cas9. With our multi-disciplinary team of world-renowned academics, drug developers and clinicians, we are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics.
19
Funding: $405.9M
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology. Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.
20
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
21
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
22
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
23
Funding: $373.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
25
Funding: $321M
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
26
Funding: $313M
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
27
Funding: $309M
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
28
Funding: $300M
Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.
Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.
29
Funding: $298.6M
Artios is developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells
Artios is developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells
30
Funding: $272.1M
Black Diamond Therapeutics is focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.
Black Diamond Therapeutics is focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.
31
Funding: $270M
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. It's also developing tools to treat medical conditions astronauts could suffer in space
32
Funding: $249.7M
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
33
Funding: $250M
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
34
Funding: $218.5M
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
35
Funding: $216.8M
Cognito Therapeutics is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.
Cognito Therapeutics is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.
36
Funding: $211M
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies.
37
Funding: $209M
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
38
Funding: $207.5M
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
39
Funding: $207.8M
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.
40
Funding: $199M
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
41
Funding: $194.2M
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
42
Funding: $189.2M
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
43
Funding: $176.2M
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
44
Funding: $170M
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
45
Funding: $165M
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
46
Funding: $163M
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections.
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections.
47
Funding: $161M
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
48
Funding: $161M
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
49
Funding: $159M
Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
50
Funding: $155.2M
Cambridge Epigenetix develops ground-breaking epigenetics tools for DNA methylation (5mC) and hydroxymethylation (5hmC) analysis.
Cambridge Epigenetix develops ground-breaking epigenetics tools for DNA methylation (5mC) and hydroxymethylation (5hmC) analysis.